Skip to main content

News

By Richard Pizzi | 10:56 am | July 29, 2009
Health and Human Services Secretary Kathleen Sebelius has announced the availability of $200 million to support grants, loans, loan repayment and scholarships to expand the training of healthcare professionals.
By Richard Pizzi | 12:00 pm | July 28, 2009
The American Hospital Association has criticized the tighter eligibility standards applied by the Department of Housing and Urban Development under new rules for refinancing hospital debt under the Section 242 Hospital Mortgage Insurance Program.
By Healthcare Finance Staff | 11:59 am | July 28, 2009
The Washington State Department of Social and Health Services is collaborating with Ingenix to help fight Medicaid fraud.
By Richard Pizzi | 11:25 am | July 28, 2009
An economist at the Economic Policy Institute criticized the Senate testimony on healthcare reform by CBO Director Douglas Elmendorf, saying one has to "spend money to save money" to reduce the growth rate of healthcare costs.
By Chelsey Ledue | 11:20 am | July 28, 2009
Obesity may cost the United States as much as $147 billion annually, based on a new study from RTI and the Centers for Disease Control and Prevention.
By Chelsey Ledue | 11:09 am | July 28, 2009
A new survey has fund that senior citizens are making drastic cuts to their medical and food budgets due to the recession.
By Eric Wicklund | 10:42 am | July 28, 2009
Former McKesson executive Duncan James has been named the QuadraMed Corporation's new chief executive officer.
By Healthcare Finance Staff | 10:38 am | July 28, 2009
Independence Blue Cross is providing digital alerts to physicians and specialists through a new messaging tool called Clinical Alerts.
By Chelsey Ledue | 12:09 pm | July 27, 2009
A patient-centered medical home pilot project that could become a model for South Carolina has completed its first quarter with 1,110 patients enrolled.
By Chelsey Ledue | 11:39 am | July 27, 2009
An expected $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic hormone-refractory population, most notably Dendreon's Provenge, according to Decision Resources.